Singapore HSA Medical Device Registration

Cisema supports your full journey through medical device registration in Singapore, from determining risk class and preparing technical documentation, to securing regulatory approval and maintaining post-market compliance. As your licensed Authorized Representative (AR) or Marketing Authorization Holder (MAH) in Singapore, we manage your product registration, act as your legal interface with the authorities, and ensure your product remains compliant with the Health Products Act.

Whether you're launching a new product, registering class B, class C, or class D medical devices in Singapore, or managing submissions involving active implantable devices, standalone medical mobile applications or in-vitro diagnostics, we bring local expertise and international coordination to every step. Our services cover everything from device description and risk analysis to compliance with essential principles, alignment with overseas reference regulatory agencies, and inspection-ready quality management system support.

Medical Device Registration in Singapore
Singapore Medical Device Registration
Indonesia Medical Device Registration

Singapore's Strategic Role

Singapore stands at the forefront of medical innovation in Asia, offering a stable, transparent, and internationally aligned regulatory environment. For medical device and IVD manufacturers looking to enter the high-potential Singapore market, understanding and complying with the Health Sciences Authority (HSA) requirements is essential to a success.

Our Services for Medical Device Registration in Singapore

Cisema manages the entire product registration process with the Health Sciences Authority HSA, aligning your strategy with current local and ASEAN regulatory requirements.

Regulatory Strategy & Classification

Determine the applicable risk classification (Class A–D) in accordance with HSA GN-13
Evaluate claims and intended use under the Health Products Act
Recommend an appropriate route such as immediate, abridged, expedited, or full evaluation
Develop a timeline and documentation roadmap including device description and validation planning and testing

Technical Documentation & Dossier Preparation

Develop a timeline and documentation roadmap including device description and validation planning and testing
Translate and localize IFUs, labels, and product documents, identifying gaps and recommending corrective actions
Draft declarations, risk analysis, and conformity statements
Ensure alignment with the HSA’s essential principles which are used to evaluate conformity.

Registration Application & Submission

Register and manage submissions through the SHARE system
Act as your point of contact for authority interactions, HSA- accredited labs or MOH partners for performance verification and clinical evaluations especially for IVDs
Sample management, testing coordination and import permits (if required)
Submit responses to deficiency letters or additional information requests
Provide real-time updates on submission progress

Post-Approval Services

Submit change notifications, renewals, and scope updates before the expiry date
Manage vigilance activities such as FSCA and adverse event reporting
Maintain HSA compliance across your product lifecycle

Optional Add-Ons

Apply under the Priority Review Scheme or Special Access Route (SAR)
Provide consultation for reclassification or ASEAN regional rollout.

Authorized Representative (AR) Services in Singapore

Foreign manufacturers of IVDs and medical devices in Singapore must appoint a local authorized representative to serve as the legal applicant and regulatory liaison. Cisema is fully licensed to represent your products before the Health Sciences Authority, ensuring you meet all registration and post-market obligations.

Legal License Holder

Maintain and update your product registration in the SHARE system
Communicate directly with the HSA on your behalf

Distributor LoAs

Listing your selected commercial partners in the SHARE system
Allow distributor changes without re-registration

Regulatory Compliance

Monitor HSA announcements and policy changes
Submit notification change requests and label or IFU updates in advance

Post-Market Vigilance

Oversee adverse event reporting and product recalls
Coordinate Field Safety Corrective Actions (FSCA) and post-market surveillance

Conformity Assessment Bodies Collaboration

Assist with ASEAN and Asia Pacific expansion planning and device classification reviews
Support implementation of a compliant quality management system

Regulatory Strategy

Collaborate with your regulatory and commercial teams across regions
Offer multilingual support and real-time updates.

Medical Device Post-Approval & Post-Market Regulatory Services in Singapore

Cisema provides ongoing post-approval and post-market regulatory support for medical devices in Singapore, helping manufacturers manage regulatory changes, safety obligations, and product lifecycle requirements.

Post-Approval Regulatory Support

Manage medical device change notifications and retention submissions
Support dealer licence amendments and renewals
Manage other regulatory updates throughout the product lifecycle

Regulatory Impact Assessment

Assess administrative and technical changes for regulatory impact
Advise on actions required to maintain regulatory compliance
Support required regulatory notifications and documentation

Post-Market Vigilance

Assess complaints and post-market information for reporting requirements
Support adverse event reporting and safety-related notifications
Coordinate reports and communications with HSA

FSCA & Recall Support

Assess and support Field Safety Corrective Actions (FSCAs)
Support medical device recalls and other corrective actions
Coordinate HSA and stakeholder follow-up

Quality Control Inspection Services for Medical Devices & IVDs in Singapore

Cisema’s quality control inspection services support your Singapore medical device & IVD operations by verifying compliance with HSA and global quality expectations. We ensure readiness for local distribution, regional supply, or internal audits.

Incoming Goods Inspections

Confirm product identity, quantity, and packaging integrity
Review labeling, certificates, and shipping documents
Verify storage and handling conditions for compliance

In-Process Quality Monitoring

Conduct on-site process checks during manufacturing or repackaging
Evaluate hygiene conditions, batch consistency, and traceability
Monitor SOP implementation and documentation practices

Final Product Release Inspections

Perform Acceptance Quality Limit-based sampling and functional testing
Confirm accuracy of IFUs and labeling
Approve readiness for market release

Special Inspection Projects

Assist with audit preparation for HSA, ISO 13485, or MDSAP
Validate reworked products, returns, or quarantined stock
Verify capital equipment serial numbers or manage recall sample checks

Singapore Medical Device Registration FAQs

All devices except Class A must be registered with HSA under the risk-based A-D classification. Devices can follow the full evaluation route, or faster, lower-cost abridged routes where they already hold approval from HSA's reference regulators. Timelines depend on class and route, so confirming eligibility for reliance early can significantly shorten time to market. Cisema can map the most efficient route for your device.

Yes. Product registration must be held by a Singapore-registered entity, and importers, wholesalers and manufacturers also require the relevant HSA dealer licences. Using an independent local registrant can make it easier to change distributors while maintaining regulatory continuity. Cisema can advise on the appropriate registrant and licensing structure for your supply chain.

Generally no. Registration is based on technical documentation (such as the ASEAN CSDT), ISO 13485 evidence, risk management and clinical evidence supporting safety and performance. Where reliance routes apply, evidence of approval from a reference regulator replaces much of the technical review. Local clinical studies are not normally expected. Cisema can review your existing evidence and identify gaps before submission.

Yes. Malaysia's MDA now accepts Class B, C and D devices already listed on Singapore's register through its Verification Route, following a pilot that ran to February 2026. In the other direction, Malaysian-registered devices benefit from an abridged route in Singapore. A Singapore registration is therefore a strong base for a staged ASEAN rollout, which Cisema can plan across its regional offices.

Registrants and dealers must report adverse events and field safety corrective actions, notify HSA of changes, maintain distribution and complaint records, and hold valid dealer licences. Registration is also maintained through ongoing HSA fees. Cisema can handle change notifications and vigilance reporting as part of an ongoing regulatory support package.

Often, yes. HSA is a well-regarded reference regulator, ASEAN markets share the CSDT dossier format, and reliance arrangements such as the HSA-MDA programme reduce duplication. Each country still requires its own registration, local representative and labelling, so the benefit comes from sequencing. Cisema has teams across Singapore, Malaysia, Vietnam, Indonesia, the Philippines and Thailand to run this as one programme.

Why Work with Cisema?

Local expertise with global reach

Our bilingual teams bridge international quality standards with local regulations

Proven track record

Over 20 years supporting market approvals and compliance in China and Asia Pacific

End-to-end solutions

From system setup to post-market surveillance, we ensure quality management and regulatory compliance throughout the product lifecycle

Industry breadth

Cross-sector expertise in life sciences, food, veterinary, consumer and industrial goods

Role of a China Agent

Explore Our Regional Medical Device & IVD Registration Support

In addition to Singapore, Cisema supports IVD and device registration, regulatory representation, and quality inspection services in:

China

Hong Kong SAR

Malaysia

Taiwan

Vietnam

Indonesia

Thailand

South Korea

India

Macao

Read the Latest Regulatory News

View More

China Issues GMP Inspection Guidelines for Sterile, Implant, IVD, Denture and Standalone Software Devices

China has introduced GMP inspection guidelines for sterile, implantable, IVD, custom-made denture and standalone software medical devices.

November 16, 2026
China Issues GMP Inspection Guidelines for Sterile, Implant, IVD, Denture and Standalone Software Devices
Two Chinese laboratory professionals check a benchtop blood analyzer as one loads a rack of capped sample tubes.

India Clarifies How Medical Device Software, and AI-Enabled Tools Are Regulated

India’s CDSCO releases final medical device software guidance under MDR 2017, outlining licensing routes, software risk classes, and cybersecurity standards.

November 16, 2026
India Clarifies How Medical Device Software, and AI-Enabled Tools Are Regulated
Two Indian clinicians review a chest X-ray on a tablet, where diagnostic software has flagged an area in one lung.

Singapore Updates GN-15 Medical Device Registration Guidance

Singapore’s HSA has revised GN-15 medical device registration guidance, updating submission templates, SaMD requirements and post-market expectations.

November 12, 2026
Singapore Updates GN-15 Medical Device Registration Guidance

Indonesia Extends Mandatory Halal Certification Deadlines

Indonesia extends halal certification deadlines for medicines, medical devices, cosmetics, and other regulated products, giving additional time to meet compliance requirements.

November 3, 2026
Indonesia Extends Mandatory Halal Certification Deadlines

China Issues Battery Registration Guidance for Active Implantable Medical Devices

See how China’s new battery registration guidance affects technical documentation, supplier coordination, and NMPA review of active implantable medical devices.

November 2, 2026
China Issues Battery Registration Guidance for Active Implantable Medical Devices

China Issues Clinical Trial Guidance for Implantable Brain-Computer Interface Systems

China's CMDE guidance defines clinical trial and registration considerations for implantable BCI devices, including patient selection, endpoints, and post-market follow-up.

November 2, 2026
China Issues Clinical Trial Guidance for Implantable Brain-Computer Interface Systems
Previous
Previous

Cisema's Singapore Office

Cisema (Singapore) Pte. Ltd.

51 Goldhill Plaza, #07-07
Singapore 308900

Contact Us

Get in Touch with Our Medical Devices Team

And discover how we can support you in achieving approval for your medical device or IVD in Singapore.

Talk to an Expert